<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348826</url>
  </required_header>
  <id_info>
    <org_study_id>SBI-FLOW</org_study_id>
    <nct_id>NCT03348826</nct_id>
  </id_info>
  <brief_title>Study of Sodium Bicarbonate in Restoring Blocked Catheters</brief_title>
  <official_title>Sodium Bicarbonate Injections for Restoration of Flow in a Central Venous Catheter (CVC/Hickman Catheter) or Peripherally Inserted Central Venous Catheter (PICC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study looking at the use of sodium bicarbonate to restore the flow of blocked
      central line devices in patients with blood cancers.

      Central line devices uses thin tubes that are placed into a vein in the body to give
      medicines, fluids, nutrients, blood products, etc.

      Sometimes, the lines become blocked. The standard procedure to get the line working again is
      to use alteplase, a protein that dissolves blood clots. While blood clotting is one cause of
      a blocked line, other reasons included the formation of calcium deposits. Sodium bicarbonate
      is routinely used in the treatment of patients receiving chemotherapy. Sodium bicarbonate is
      a liquid drug which is capable of dissolving protein and calcium deposits.

      This study will compare whether sodium bicarbonate works just as well as alteplase to recover
      the function of a blocked line.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2, 2018</start_date>
  <completion_date type="Anticipated">April 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful clearance rate of sodium bicarbonate</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful clearance rate of alteplase</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">608</enrollment>
  <condition>Cancer</condition>
  <condition>Central Venous Catheterization</condition>
  <arm_group>
    <arm_group_label>Alteplase then Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate then Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate 8.4% Solution for Injection</intervention_name>
    <description>3 mL injection into line with up to 2 injections administered</description>
    <arm_group_label>Alteplase then Sodium Bicarbonate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate then Alteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase Injectable Solution</intervention_name>
    <description>2 mL injection into line with up to 2 injections administered</description>
    <arm_group_label>Alteplase then Sodium Bicarbonate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate then Alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematology patients with indwelling CVC/PICC line.

          -  Patients continuing to receive chemotherapy treatment for consolidation,
             intensification and maintenance regimens in hematological malignancies such as in
             acute leukemia, lymphoma, myelodysplastic syndrome, supportive care measures using
             blood products, ongoing anti-infective treatments, and nutrition.

          -  Patients whose CVC/PICC line becomes obstructed during routine care are being
             identified and presented to attending physician and pharmacist.

          -  Mechanical obstruction having been ruled out by visual inspection and manipulation of
             the patient's posture or extremities or both.

        Exclusion Criteria:

          -  Patients with hemodialysis line occlusions

          -  Anyone with documentation of prior history of alteplase allergy or hypersensitivity
             reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Minden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Minden, M.D.</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>2838</phone_ext>
    <email>mark.minden@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Minden, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mark Minden, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

